Pain Therapeutics Gets Investors' Painkiller Suit Nixed

Law360, New York (September 26, 2012, 8:14 PM EDT) -- A Texas federal judge on Wednesday dismissed a class action alleging Pain Therapeutics Inc.'s brass misled investors into thinking the biopharmaceutical company's newly developed painkiller would receive U.S. Food and Drug Administration approval, when it ultimately did not.

In granting PTI's motion to dismiss, U.S. District Judge Sam Sparks said the shareholders who brought the suit had not sufficiently pled allegations that PTI's chief executive and other directors intentionally deceived investors into thinking Remoxy, a less addictive form of oxycodone, would get FDA approval and go...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

KB Partners I, LP et al v. Barbier et al


Case Number

1:11-cv-01034

Court

Texas Western

Nature of Suit

Securities/Commodities

Judge

Sam Sparks

Date Filed

December 2, 2011

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.